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Abstract
Background Neonatal immunization with hepatitis B
(HB) vaccine induces protective levels of antibody (anti-
HBs C10 IU/L) in a majority of vaccines. However, the
duration of protection after HB vaccination in infants is
unknown. A smaller proportion of children vaccinated
beginning at birth with three doses of HB vaccine were
found to have protective titers 5–10 years after initial
vaccination. Long-term efficacy of HB vaccine depends
mainly on peak antibody levels after vaccination, and
subjects were observed to have lower levels of antibodies if
they received the first dose of vaccine immediately after
birth. The aim of our study was to compare the immuno-
genicity of two different HB vaccine schedules in infants
born to HB surface antigen-negative mothers.
Methods Anti-HBs titers in infants vaccinated with two
different schedules were compared. Infants were vacci-
nated at 0, 2, and 9 months (group 1) or at 2, 4, and
9 months (group 2). In total, 267 blood samples were
analyzed at a mean of 14.20 ± 2.39 months after the third
vaccine dose. Sera were tested for hepatitis B surface
antigen (HBsAg), hepatitis B surface antibody (anti-HBs),
and hepatitis B core antibody (anti-HBc) using commercial
enzyme immunoassay kits.
Results The geometric mean titers for anti-HBs were
95.00 and 379.51 IU/L and the rates of anti-HBs more than
C100 IU/L were 57.7 and 94.9% in group 1 and 2 infants,
respectively.
Conclusion Delaying the first dose of the HB vaccine
until 2 months after birth produces a higher immune
response and can provide longer term protection.
Keywords Hepatitis B vaccine  Immunity duration 
Immunogenicity  Schedules
Introduction
Safe and effective vaccines against hepatitis B (HB)
infection have been available since 1982. The World
Health Organization (WHO) recommends universal vac-
cination against HB to ultimately eliminate HB; this rec-
ommendation had been progressively implemented, with
168 countries having with a universal immunization pro-
gram by the end of 2006 [1].
Neonatal vaccines have certain medical advantages,
namely, they produce early protection for the vulnerable
newborn period, and there is the advantage of birth cohort
accessibility. However, newborns do have impaired immune
responses due to a range of deficiencies in both adaptive
immunity and innate immunity as well as the potentially
suppressive effects of maternally derived antibodies [2].
The duration of protection after HB vaccination of
infants vaccinated at birth is unknown, although more
recent studies have found that after neonatal immunization
with HB vaccine, a large proportion of the children,
especially adolescents, exhibited waning immunity. Such
decreased protection poses the risk of breakthrough infec-
tion [3–5]. It is generally assumed that the long-term effi-
cacy of HB vaccine depends primarily on peak antibody
levels after vaccination. The study of McMahon et al. [6]
revealed that children vaccinated in early childhood were
more likely to have undetectable levels of hepatitis B
S. Agladioglu  U. Beyazova  A. D. Camurdan (&) 
F. Sahin  A. Atak




surface antibody (anti-HBs) in late adolescence or young
adulthood, when the risks for HB infection increase. Other
studies have shown that lower seroconversion rates
occurred in children after primary vaccination if they had
received the vaccine immediately after birth [7–9].
Universal HB immunization began in 1998 in Turkey
[10]. Children born to seronegative mothers were vacci-
nated according to the 2–4–9 (age in months) schedule
between 1998 and 2002; thereafter, the vaccination sche-
dule was changed to 0–2–9 months and remained so until
2007. Since 2008, the 0–1–6 vaccination scheme has been
applied [11]. The aim of this study was to compare the
immunogenicity of HB vaccine administered in the two
different vaccination schemes starting either at month 2 of
life or at birth.
Materials and methods
Subjects
This descriptive cross-sectional study was performed at the
Gazi University Faculty of Medicine Well-Child Clinic
between June 2004 and June 2005. The study cohort con-
sisted of all infants who made routine well-child visits to
the clinic, whose parents gave informed consent for the
study, and who fulfilled the following inclusion criteria: (1)
age between 18 and 30 months; (2) made regular visits to
the clinic for routine check-ups; (2) were born to hepatitis
B surface antigen (HBsAg)-negative mothers; (4) showed
no sign of chronic disease; (5) gestational age was
[37 weeks and birth weight was [2,000 g; (6) primary
hepatitis B vaccination program was completed in this
clinic according to either the 0–2–9 or 2–4–9 schedule.
A total of 267 infants satisfied all inclusion criteria and
were enrolled in the study. Of these, 111 infants received
three doses of vaccine at months 0, 2, 9 (group 1) and 156
infants received three doses of vaccine at months 2, 4, 9
(group 2). Vaccines for diphtheria, pertussis, tetanus, and
live polio were concomitantly given at the second and
fourth months. Age and anti-HBs values of the mothers and
gestational age, birth weight, and gender of the child were
recorded on the well-child visit chart.
Ethical aspects
The study protocol was approved by the ethical committee
of Gazi University Medical Faculty.
Vaccines
All infants were administered 0.5 ml (10 lg) of Euvax B
vaccine, which is provided in the form of 10-ml glass vials
(LG Life Sciences, Iksan-si, Korea). The vaccine contains
10 mg purified HBsAg (Saccharomyces cerevisiae is pro-
duced by recombinant DNA technology in yeast cells),
0.25 mg aluminum hydroxide gel, and 0.01% (w/v) thio-
mersal. The vaccines were always stored at 2–8C and
given intramuscularly in the anterolateral thigh according
to either of one of the vaccination schedules.
Laboratory methods
Hepatitis B surface antigen, anti-HBs, and hepatitis B core
antibody (anti-HBc) were measured by enzyme-linked
immunosorbent assays (ELISA) using commercial test kits
(UniCel DxI 800 System; Beckman Coulter, CA) in
accordance with the manufacturer’s instructions. Anti-HBs
is expressed in international units per liter (IU/L) after
comparison with the WHO reference standard. The lower
limit of detection for the ELISA was 5 IU/L. Serum sam-
ples were studied on the same day. All children with an
anti-HBs concentration C10 IU/L were considered to be
seroprotected.
Statistical methods
Statistical analysis was performed using SPSS ver. 15.0
software (SPSS, Chicago, IL). Descriptive values for con-
tinuous variables were given as the mean ± standard
deviation (SD), while categoric variables were expressed as
number and percentage. All data were tested for normal
distribution, and comparisons were made with parametric
and nonparametric tests for normally distributed and non-
normally distributed variables, respectively. The Spearman
correlation test was performed for the correlation analysis.
Anti-HBs concentrations were log-transformed prior to
calculating the geometric mean titer (GMT). For analytic
purposes, children with undetectable anti-HBs were
assigned a value of 2.5 IU/L. A t test was used to compare the
log-transformed peak anti-HBs concentrations, while pro-
portions were compared using a chi-square tests. A p value
\0.05 was considered to be statistically significant.
Results
All 267 infants who participated in the study showed no
evidence of HB infection. The mean age of the children was
23.22 ± 2.36 months (minimum 18, maximum 30, median
24 months). Duration after primary immunization and blood
sampling for both groups was 14.22 ± 2.36 months (min-
imum 9, maximum 21, median 15 months). The quantita-
tive anti-HBs value for 12 mothers (1 in group 1, 11 in
group 2) could not be obtained because they were measured
in another laboratory; these mothers were therefore
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excluded from the study. There were no significant differ-
ences between the two groups in terms of the age or the anti-
HBs GMT levels of the mothers, gestational age, mean
interval between the last dose of HB vaccine and blood
sampling, and birth weight or gender of the infants
(Table 1).
There was no correlation between the anti-HBs levels of
mothers and infants (p = 0.850).
Anti-HBs GMT levels of infants in group 1 and 2 were
95.00 and 379.51 IU/L respectively (p = 0.0001).
Figure 1 shows the frequencies of protective levels of
anti-HBs after primary vaccination in the two different
vaccination schemes. Anti-HBs levels C10 IU/L after pri-
mary vaccination in infants who received the first vacci-
nation at month 2 (group 2) and at birth (group 1) were
99.4 and 90.1%, respectively (Fisher’s Exact test
p = 0.0001).
In terms of long-term protection, anti-HBs levels
C100 IU/L were considered to be important. In infants
whose first dose of HB vaccination was received at
2 months of age, 94.9% had anti-HBs levels C100 IU/L
after the primary vaccination, while in infants whose vac-
cination started at birth, this was only 57.7% (Fisher’s
Exact test p = 0.0001). When factors associated with long-
term protection were analyzed, prenatal anti-HBs level of
the mother (p = 0.197), gestational age (B37 weeks)
(p = 0.576), and gender (p = 0.305) were statistically
insignificant. Antibody titers C100 IU/L were 13.59-fold
higher in the infants of group 2 than in those of group 1
(odds ratio 13.59, 95% confidence interval 5.77–33.14;
p = 0.0001).
Discussion
Members of the medical profession consider an anti-HBs
level C10 IU/L to be protective against HB infection [12];
in addition, an anti-HBs level C100 IU/L is taken as evi-
dence of long-lasting immunity [13]. The duration of
immunity after HB vaccination is currently unknown, but it
is generally assumed that the higher the antibody levels
after vaccination, the longer the period of protection
[13–15]. Our study shows that although the vaccine was
highly immunogenic in both of the vaccination schemes
investigated, the scheme starting at the end of second
month of life yielded a significantly higher immunogenic-
ity than that starting at birth. Only limited data are cur-
rently available to compare alternate schedules against the
conventional schedule, but our results do confirm those
from a number of previous studies [7, 8, 16]. The subjects
in these three studies were all infants of HBsAg-negative
mothers, and the results showed that these infants had
lesser seroconversion if they received the first dose of HB
vaccine immediately after delivery instead of 2 months
Table 1 Characteristics of study groups
Group 1a (n = 111) Group 2b (n = 156) Total (n = 267) p
Children
Mean age (months) 23.12 ± 2.61 23.29 ± 2.17 23.22 ± 2.36 0.540
Gender (n)
Male 60 75 135 0.336
Female 51 81 132
Gestational age (weeks) 38.68 ± 1.07 38.71 ± 1.16 38.7 ± 1.12 0.813
Birth weight (g) 3,248 ± 384.5 3,340 ± 433.3 3,301 ± 415.4 0.075
Mother’s age (years) 29.01 ± 4.6 29.66 ± 4.5 29.39 ± 4.57 0.259
Anti-HBs GMT (IU/L) 95.00 379.51 0.0001
Positive anti-HBs (%)c 90.1 99.4 0.0001
Group 1a (n = 110) Group 2b (n = 145) Total (n = 255) p
Mothers
Prenatal Anti-HBs GMT of mothers (IU/L) 6.349 5.140 0.297
Prenatal Anti-HBs titer C 10 IU/L of mothers (%) 25.2 25 0.357
GMT, Geometric mean titer; anti-HbBs, hepatitis B surface antibody
Where appropriate, data are given as the mean ± standard deviation (SD)
a Group 1, infants who received three doses of hepitatis B (HB) vaccine at months 0, 2, 9 of life
b Group 2, infants who received three doses of HB vaccine at months 2, 4, 9 of life
c Anti-HBs [10 IU/L
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after birth. In another study on the protective effects of HB
vaccine in infants of HBsAg-positive mothers who were
followed up for 36 months, HB infections were observed to
be more frequent in infants whose vaccination started at
birth [17], likely due to the insufficient maturation of the
immune system in newborn infants. Furthermore, mater-
nally derived antibodies can interfere with active immu-
nization. Weeratna et al. [18] showed that B cell responses
remained weak when newborn mice were immunized
against HBsAg in the presence of high levels of maternal
antibody against HBsAg, and Hu et al. [19] showed that
passively acquired maternal anti-HBs in infants may, to
some extent, impair the antibody response to HB vaccine.
In our study, there were no differences between the anti-
HBs levels of mothers of the two groups in pregnancy,
whereas infants showed lower seroconversion if they
received the first dose of HB vaccine immediately after
delivery. We consider the immunological immaturity of the
newborn to be the predicting factor of antibody levels in
the postvaccination period.
A number of studies have shown that persistence of HBs
antibodies is not long term in babies who are vaccinated at
birth. In two studies of children 5–6 years after they had
received the primary vaccination with recombinant HB
vaccine, Petersen et al. [20] found that 12.5% and Seto
et al. [21] found that 19% of the children had protective
levels of anti-HBs antibodies. In comparison, West et al.
[22] found that the anti-HBs titer was C10 after 12 years in
all of the children vaccinated with plasma-derived HB
vaccine 2–3 months after birth.
Stevens et al. [9] showed that the immune response was
enhanced by delaying the initial injection to 1 month after
birth and the third injection to 6–9 months of age. A
number of authors reported that in their studies the con-
centrations of anti-HBs after the third injection were
dependent on the interval between the second and the third
dose. Children receiving the third vaccine dose relatively
late developed antibody titers higher than those receiving
the third dose on schedule [13, 14, 23]. In our study, the
interval between the second and third doses for those
infants vaccinated at birth was longer than that for infants
vaccinated at the second month, but we did not observe any
positive impact of this difference on antibody levels.
At the present time, there are no assays to measure
correlates of protection against HB infection directly [24].
It is therefore possible that immunological memory itself
depends on the development of a protective level of anti-
bodies after vaccination. However, there is a strong belief
that a high proportion of children vaccinated in early
childhood retain immune memory and develop an anti-HBs
response upon exposure to HB later in life. Thus, even if
anti-HBs concentrations decline to \10 IU/L, immune
memory would continue to persist over a longer time [1,
25]. It is likely that vaccinated children born to HBsAg-
positive mothers or living in areas where HB infection is
endemic are exposed to HB throughout childhood. Such
children can obtain natural booster doses. However, the
duration of immunity among children born to HBsAg-
negative mothers or those living in low endemicity settings
may be shorter due to the absence of natural boosting.
Turkey is known to have moderate HB endemicity [26];
thus children born to HBsAg-negative mothers need long-
term protectivity. If immunological memory may later
decline or become undetectable, the risk of breakthrough
infection may occur. Some countries have chosen not to
implement immunization at birth and instead screen preg-
nant women for HBsAg [27]. The HB vaccine birth dose is
then given only to infants born to HBsAg-positive mothers.
In our country, the initial vaccination for infants born to
HBsAg-negative mothers (in many metropolises HB
markers can be screened) may be delayed until a few
months after birth, the first vaccination time of other rou-
tine infant vaccine antigens (DaPT–IPV–Hib and conju-
gated pneumococcus). This vaccination can be easily
performed in combination with other vaccines, thus
reducing the number of required injections, simplifying
administration and improving immunization rates.
Screening also enables medical professionals to identify
HB carriers, thereby providing an opportunity to give HB
immunoglobulin to infants born to these mothers. How-
ever, screening is costly and not usually feasible in
developing countries. In countries where screening pro-
grams for pregnancy are not available, vaccination at birth
for HB perinatal infections is still a necessity. However,
such infants should be followed up to evaluate whether or
not they will have long-term immunity. Our study is a
preliminary report, and we plan to follow up these infants
until puberty and evaluate their immunological status.
Fig. 1 Immunological responses in two different Hepatitis B vacci-
nation schedules
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